Activity in this selectionMar 31, 2026 · AI · Mar 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- —
1 roles undisclosed- New companies
- 1
First participation on record · 0 follow-on- Funding in participating rounds
- $9.3M
1 disclosed · full round size, not this investor’s share
Rounds
1 in this selectionAntiverseDevelops therapeutic antibodies for challenging disease targets using AI-driven techbio
Role not disclosed